Evidence map›Paper›PMID 40965024›Full record

ArticleMedicinal chemistry (Shariqah (United Arab Emirates))2026

Discovery of Novel 1,3,4-oxadiazole-based Inhibitors Against Urease and Diabetes: Design, Synthesis, SAR, Biological, and Molecular Docking Screening.

Sabeen Arshad, Aneela Maalik, Wajid Rehman, Yousaf Khan, Hina Sarfraz, Liaqat Rasheed, Mohammed B Hawsawi, Mustafa S Alluhaibi, Majed Alharbi

Abstract read
PubMed Publisher
In one paragraph

Article in Medicinal chemistry (Shariqah (United Arab Emirates)), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sabeen ArshadDepartment of Chemistry, COMSATS University Islamabad campus-45550, Islamabad, Pakistan.
Aneela MaalikDepartment of Chemistry, COMSATS University Islamabad campus-45550, Islamabad, Pakistan.
Wajid RehmanDepartment of Chemistry, Hazara University, Mansehra-21120, Pakistan.
Yousaf KhanDepartment of Chemistry, COMSATS University Islamabad campus-45550, Islamabad, Pakistan.
Hina SarfrazDepartment of Chemistry, Quaid-i-Azam University, Islamabad, 45320, Islamabad, Pakistan.
Liaqat RasheedHenan International Joint Laboratory of Nano-Photoelectric Magnetic Material, School of Material Science and Engineering, Henan University of Technology, Zhengzhou, 450001, Henan, China.
Mohammed B HawsawiDepartment of Chemistry, Faculty of Science, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
Mustafa S AlluhaibiDepartment of Chemistry, Faculty of Science, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
Majed AlharbiDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHeterocyclic compounds bearing oxygen and nitrogen atoms are key pharmacophores in modern drug design. Among them, 1,3,4-oxadiazoles are notable for their diverse biological activities, including anti-inflammatory, anticancer, antidiabetic, antibacterial, and enzyme inhibitory effects. This study focuses on the synthesis and evaluation of indazole-based 1,3,4-oxadiazole-benzenesulfonothioate hybrids as potential therapeutic agents.

methodsA multistep synthetic route was employed to develop a series of eighteen (18) analogues. The synthetic strategy involved the formation of methyl 5-methyl-1H-indazole-3-carboxylate, conversion to carbohydrazide, cyclization with CS2, and final coupling with substituted benzenesulfonyl chlorides to yield the target hybrids (1-18).

resultsThe urease inhibition potential of scaffolds ranged from IC DISCUSSION: The enhanced activity of compounds bearing electron-withdrawing groups (F, NO

conclusionThe synthesized 1,3,4-oxadiazole derivatives demonstrate promising dual inhibitory activity against urease and α-glucosidase, suggesting their potential as lead compounds in the treatment of gastric infections and diabetes. This study contributes to the ongoing development of multifunctional therapeutic agents with improved efficacy and selectivity.

Indexed as

Diabetes MellitusDrug DesignEnzyme InhibitorsHypoglycemic AgentsOxadiazolesUreaseHumansMolecular Docking SimulationMolecular StructureStructure-Activity Relationship1,3,4-oxadiazoleEnzyme InhibitorsHypoglycemic AgentsOxadiazolesUreasebenzenesulfonyl chloridecomputational studiesoxadiazoleSARSynthesisureaseα-glucosidase

Identifiers

PMID40965024

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.